HAEMONETICS CORP — Director's Dealing 2020

Jun 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2020-06-12

Reporting Person: Simon, Christopher (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-12	Common Stock	A	102064	—	Acquired	417411	Direct
2020-06-12	Common Stock	S	1294	$89.29	Disposed	416117	Direct
2020-06-15	Common Stock	S	45723	$87.71	Disposed	370394	Direct

Footnotes

F1: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020.

F2: This number includes unvested restricted stock units ("RSUs") previously reported.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.